Overview Fundamentals API Earnings EOD API Sample Code Pricing

Ligand Pharmaceuticals Inc General Contingent Value Rt (LGNYZ PINK) stock market data APIs

$0.003 0(0%) as of July 25, 2024
Price chart is built with Anychart

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Ligand Pharmaceuticals Inc General Contingent Value Rt Financial Data Overview

0.003
0.003
-
0.003
0.003
0.0012-0.0097
0
0
118 M
0.918
Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'LGNYZ',
Type: 'Common Stock',
Name: 'Ligand Pharmaceuticals Inc General Contingent Value Rt',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000S8JF16',
ISIN: NULL,
CUSIP: NULL,
CIK: '886163',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: '',
Industry: '',
HomeCategory: NULL,
IsDelisted: false,
}

Ligand Pharmaceuticals Inc General Contingent Value Rt Fundamental Data is available in our Financial Data APIs

  • Net Revenue 118 M
  • EBITDA 33 892 K
  • Earnings Per Share
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get Ligand Pharmaceuticals Inc General Contingent Value Rt Earnings via APIs

  • Latest Release NaN
  • EPS/Forecast NaN

Get Ligand Pharmaceuticals Inc General Contingent Value Rt End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?
support@eodhistoricaldata.com